[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:idiopathic-short-stature":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":34,"states":35},"Idiopathic Short Stature",4,[7,15,22,28],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT06382155","A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature",[11],"Phase 2","RECRUITING","2026-08-26T02:19:25.538428Z","2026-07-05T05:32:16.750337Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":20,"content_modified":21},"NCT07226089","Comparison of Weekly Somatrogon to Daily Genotropin in Children Born Small for Gestational Age or With Idiopathic Short Stature.",[19],"Phase 3","2026-08-26T02:17:35.666428Z","2026-05-13T02:55:06.678830Z",{"nct_id":23,"title":24,"phases":25,"status":12,"updated_at":26,"content_modified":27},"NCT07221851","Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders",[19],"2026-08-26T02:16:55.892527Z","2026-05-05T02:35:31.682773Z",{"nct_id":29,"title":30,"phases":31,"status":12,"updated_at":32,"content_modified":33},"NCT06309979","A Study to Assess Growth in Children With Idiopathic Short Stature",[],"2026-08-26T02:18:38.077159Z","2026-05-13T02:55:06.435914Z",[],[36,39,42,45,48,51,55,58,61],{"state":37,"count":5,"slug":38},"California","california",{"state":40,"count":5,"slug":41},"Florida","florida",{"state":43,"count":5,"slug":44},"Minnesota","minnesota",{"state":46,"count":5,"slug":47},"New York","new-york",{"state":49,"count":5,"slug":50},"Texas","texas",{"state":52,"count":53,"slug":54},"Georgia",3,"georgia",{"state":56,"count":53,"slug":57},"Idaho","idaho",{"state":59,"count":53,"slug":60},"Louisiana","louisiana",{"state":62,"count":53,"slug":63},"Washington","washington"]